Option Deal Structure Works For Myriad As It Moves To Buy Crescendo

Having watched Crescendo Bioscience gain a foothold in the market for inflammatory and autoimmune diagnostics, Myriad Genetics is now moving to acquire the company – a right it obtained via a novel strategic investment agreement in 2011.